Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA; 2013.
   Google Scholar
• National Institute of Mental Health. Mental Health Information. Bipolar Disorder [Internet]. 2017 [cited 2020 Aug 11]. Available from: https://www.nimh.nih.gov/health/statistics/bipolar-disorder.shtml
   Google Scholar
• Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
   PubMed Web of Science ®Google Scholar
• Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–S11.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019;35(11):1993–2005.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58–66.
   PubMed Web of Science ®Google Scholar
• Bessonova L, Ogden K, Doane MJ, et al. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481–497.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Greene M, Guerin A, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51.
   PubMed Web of Science ®Google Scholar
• Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry. 2017;16(1):9.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. J Comp Eff Res. 2019;8(4):217–227.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Greene M, Paladini L, Lemmer T, et al. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. Neuropsychiatr Dis Treat. 2018;14:1545–1559.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Medicaid’s role in financing behavioral health services for low-income individuals. 2017 [cited 2021 Mar 1]. Available from: https://www.kff.org/medicaid/issue-brief/medicaids-role-in-financing-behavioral-health-services-for-low-income-individuals/
   Google Scholar
• Thomas MR, Waxmonsky JA, Gabow PA, et al. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. Psychiatr Serv. 2005;56(11):1394–1401.
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE, Li H, et al. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. Psychiatr Serv. 2007;58(8):1073–1078.
   PubMed Web of Science ®Google Scholar
• Chapel JM, Ritchey MD, Zhang D, et al. Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries. Am J Prev Med. 2017;53(6S2):S143–S154.
   PubMed Web of Science ®Google Scholar
• Jing Y, Kim E, You M, et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ. 2009;12(2):104–113.
   PubMedGoogle Scholar
• Jing Y, Johnston SS, Fowler R, et al. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. J Med Econ. 2011;14(6):777–786.
   PubMedGoogle Scholar
• Ng-Mak D, Halpern R, Rajagopalan K, et al. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics. Curr Med Res Opin. 2019;35(2):211–219.
   PubMed Web of Science ®Google Scholar
• United States Congress. Health Insurance Portability and Accountability Act of 1996. 104-191. 1996 Aug 21.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Fewell Z, Hernán MA, Wolfe F, et al. Controlling for time-dependent confounding using marginal structural models. The Stata J. 2004;4(4):402–420.
   Web of Science ®Google Scholar
• Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–560.
   PubMed Web of Science ®Google Scholar
• Ostacher M, Ng-Mak D, Patel P, et al. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. World J Biol Psychiatry. 2018;19(8):586–601.
   PubMed Web of Science ®Google Scholar
• Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154–184.
   PubMed Web of Science ®Google Scholar
• Florida Medicaid Drug Therapy Management Program for Behavioral Health. 2019–2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. Canada: University of South Florida; 2020.
   Google Scholar
• Tocco M, Newcomer JW, Mao Y, et al. 160 Lurasidone and metabolic syndrome: results from short- and long-term clinical studies in patients with bipolar depression. CNS Spectr. 2020;25(2):302–303.
   Google Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105.
   PubMed Web of Science ®Google Scholar
• Orsolini L, De Berardis D, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020;19(8):981–998.
   PubMed Web of Science ®Google Scholar
• Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry. 2009;8(1):7.
   PubMedGoogle Scholar
• Broder MS, Greene M, Chang E, et al. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder. J Med Econ. 2019;22(1):63–70.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Wade SW, Bong-Chul C, et al. Adherence to lurasidone and other atypical antipsychotics among patients with bipolar disorder: a real world assessment. J Health Med Econ. 2016;2(2):7.
   Google Scholar